COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases
Copyright © 2023 Gauckler, Kesenheimer, Geetha, Odler, Eller, Laboux, Alberici, Zappa, Chebotareva, Moiseev, Bonilla, Jhaveri, Oniszczuk, Audard, Costa, Mastroianni-Kirsztajn, Bruchfeld, Muto, Windpessl, Mayer and Kronbichler..
Introduction: Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce.
Methods: We created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes.
Results: Fifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having "non-severe" COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p <.001) and ongoing intake of corticosteroids at presentation (p = .047) were also significantly associated with severe COVID-19 outcomes, while the overall use of ongoing immunosuppressive agents and glomerular disease remission status showed no significant association with the severity of COVID-19 (p = .430 and p = .326, respectively).
Conclusion: Older age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 14(2023) vom: 15., Seite 1228457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gauckler, Philipp [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune disease |
|---|
| Anmerkungen: |
Date Revised 03.10.2023 published: Electronic-eCollection Citation Status Publisher |
|---|
| doi: |
10.3389/fimmu.2023.1228457 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362633614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362633614 | ||
| 003 | DE-627 | ||
| 005 | 20231226210946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1228457 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362633614 | ||
| 035 | |a (NLM)37767096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gauckler, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Gauckler, Kesenheimer, Geetha, Odler, Eller, Laboux, Alberici, Zappa, Chebotareva, Moiseev, Bonilla, Jhaveri, Oniszczuk, Audard, Costa, Mastroianni-Kirsztajn, Bruchfeld, Muto, Windpessl, Mayer and Kronbichler. | ||
| 520 | |a Introduction: Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce | ||
| 520 | |a Methods: We created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes | ||
| 520 | |a Results: Fifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having "non-severe" COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p <.001) and ongoing intake of corticosteroids at presentation (p = .047) were also significantly associated with severe COVID-19 outcomes, while the overall use of ongoing immunosuppressive agents and glomerular disease remission status showed no significant association with the severity of COVID-19 (p = .430 and p = .326, respectively) | ||
| 520 | |a Conclusion: Older age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a autoimmune disease | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a glomerulonephritis | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a kidney disease | |
| 650 | 4 | |a risk factor | |
| 700 | 1 | |a Kesenheimer, Jana S |e verfasserin |4 aut | |
| 700 | 1 | |a Geetha, Duvuru |e verfasserin |4 aut | |
| 700 | 1 | |a Odler, Balazs |e verfasserin |4 aut | |
| 700 | 1 | |a Eller, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Laboux, Timothee |e verfasserin |4 aut | |
| 700 | 1 | |a Alberici, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Zappa, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Chebotareva, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Bonilla, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Jhaveri, Kenar D |e verfasserin |4 aut | |
| 700 | 1 | |a Oniszczuk, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Audard, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni-Kirsztajn, Gianna |e verfasserin |4 aut | |
| 700 | 1 | |a Bruchfeld, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Windpessl, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Kronbichler, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 15., Seite 1228457 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:15 |g pages:1228457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1228457 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 15 |h 1228457 | ||